Kiniksa Pharmaceuticals Intern - COM (KNSA)

CUSIP: G5269C101

Q1 2021 13F Holders as of 31 Mar 2021

Type / Class
Equity / COM
Total 13F shares
29,045,474
Share change
-727,853
Total reported value
$537,618,213
Put/Call ratio
140%
Price per share
$18.51
Number of holders
103
Value change
-$12,626,294
Number of buys
48
Number of sells
59

Quarterly Holders Quick Answers

What is CUSIP G5269C101?
CUSIP G5269C101 identifies KNSA - Kiniksa Pharmaceuticals Intern - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q1 2021

As of 31 Mar 2021, Kiniksa Pharmaceuticals Intern - COM (KNSA) was held by 103 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 29,045,474 shares. The largest 10 holders included HILLHOUSE CAPITAL ADVISORS, LTD., VANGUARD GROUP INC, BAKER BROS. ADVISORS LP, PICTET ASSET MANAGEMENT LTD, BlackRock Inc., STATE STREET CORP, AMERIPRISE FINANCIAL INC, Avidity Partners Management LP, JANUS HENDERSON GROUP PLC, and CITADEL ADVISORS LLC. This page lists 103 institutional shareholders reporting positions in this security for the Q1 2021 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.